Date: 2017-05-03
Type of information: Nomination
Compound: chief medical officer
Company: Rigontec (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 3, 2017, Rigontec announced the appointment of industry veteran Prof. Eugen Leo as Chief Medical Officer. Prof. Leo brings to Rigontec more than 15 years of experience in conducting phase I-III development of innovative anti-cancer compounds such as kinase inhibitors, antibodies, vaccines and antisense molecules, with a major focus on immuno-oncology. He will lead the global clinical development of RGT100 and will report to Dr. Christian Schetter, CEO of Rigontec.
- Dr. Eugen Leo is a board-certified Hematologist and Medical Oncologist, Professor of Medicine and targeted therapy development specialist. Previously, he served in various positions with growing responsibilities up to Vice President level within both biotechnology (Micromet) and large pharmaceutical companies (Johnson&Johnson, Merck-Serono). He has been instrumental for reaching proof-of-concept for the BiTE platform (blinatumomab) and development of various other first-in class molecules in the immuno-oncology space. He studied medicine at the Universities of Freiburg, Münster, Heidelberg (Germany) and Cincinnati (USA). Dr. Leo is ESMO-certified, holds an M.B.A. from Colorado State University, is founder of LeoConsulting/Munich and currently also serves as Head of Clinical Development for Isarna Therapeutics GmbH, Munich.
Financial terms:
Latest news:
Is general: Yes
